Vedanta Biosciences completes $68 million Series D financing

21 July 2021

USA-based microbiome company Vedanta Biosciences today announced the closing of a $68 million Series D financing.

Vedanta, an affiliate of London-listed PureTech Health (LSE: PRTC), plans to use the proceeds to advance its pipeline of defined bacterial consortia, including progressing VE303 into a Phase III clinical trial in patients at high risk for recurrent CDI, initiating a Phase II clinical trial of VE202 in mild to moderate ulcerative colitis, and continuing to advance programs in additional indications.

Significant progress since last funding

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK